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Introduction: Combined antiretroviral therapy (cART) in the treatment of HIV-1 infection has been associated with
complications, including lipodystrophy, hyperlipidaemia, insulin resistance (IR) and diabetes.
Aims: To compare the prevalence of glucose homeostasis disturbances and IR in HIV patients on cART according to
the presence of lipodystrophy (defined clinically and by Fat Mass Ratio) and different patterns of fat distribution and
to establish their associations.
Design: Cross-sectional cohort study.
Methods: We evaluated body composition and IR and insulin sensitivity indexes in 345 HIV-infected adults.
Results: Patients with clinical lipodystrophy (CL) had higher plasma glucose levels than patients without CL,
without significant differences in plasma insulin levels, A1c, HOMA-IR, HOMA-B, QUICKI, or MATSUDA index. Patients
with lipodystrophy defined by FMR had higher plasma glucose and insulin levels, A1c, HOMA-IR, QUICKI and
MATSUDA than patients without lipodystrophy, without differences in HOMA-B. Higher insulin resistance (HOMA-IR
≥ 4) was present in patients with FMR-defined lipodystrophy. Patients with FMR-defined lipodystrophy had a higher
prevalence of IFG, IGT and DM than patients without lipodystrophy. Significant associations between HOMA-IR and
total, central and central/peripheral fat evaluated by CT at abdominal level were found and no association between
HOMA-IR and peripheral fat. Association between HOMA-IR and total and trunk fat but no association with leg and
arm fat (evaluated by DXA) was found.
Conclusions: IR and glucose disturbances were significantly increased in patients with FMR-defined lipodystrophy.
FMR lipodystrophy definition seems to be a more sensitive determinant of insulin resistance and glucose
disturbances than clinical definition.
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Combined antiretroviral therapy (cART) in the treat-
ment of HIV-1 infection confers significant survival
benefit and has altered the natural history of this disease
[1]. However, cART has been associated with metabolic
complications, including hyperlipidemia, insulin resist-
ance (IR), diabetes mellitus (DM) and lipodystrophy,
with resultant increased risk of cardiovascular disease
[2].
DM is a known complication of several antiretroviral
therapies, being associated with both short [3,4] and
long-term [5,6] exposure to some of these drugs [7]. The
reported prevalence of DM in HIV-infected populations
ranges from 2 % to 14 %, with differences in prevalence
explained by differences in demographic characteristics,
lifestyle, and antiretroviral exposure [7-11]. Some studies
have suggested an increased risk of premature cardiovas-
cular disease in HIV-infected individuals, and have high-
lighted the need to understand the relationship of HIV
infection and cART with the risk of DM, a primary car-
diovascular risk factor [12,13]. Diabetes is associated
with IR, and IR among treated HIV-infected patients is
multifactorial: in addition to the common contributors
to IR (e.g. obesity, physical inactivity and genetic influ-
ences), antiretroviral drugs and lipodystrophy or altera-
tions in body fat distribution are also involved [5]. The
term “HIV-associated lipodystrophy syndrome” was
coined, but it soon became clear that some patients have
pure lipoatrophy, while others have central fat accumu-
lation, and a subset of patients have a mixed picture of
both morphologic features. As in congenital lipodystro-
phy, lipodystrophy related to HIV-infected patients is
also associated with IR and overt DM [12,14,15].
The aim of this study was to compare the prevalence
of glucose homeostasis disturbances and IR in HIV-
infected adult patients on cART according the presence
of lipodystrophy [clinically defined and FMR-defined
determined by whole-body dual-energy X-ray absorpti-
ometry (DXA)] and to different patterns of fat distribu-
tion, and to establish the main contributors to these
alterations in HIV-infected adults.Methods
Subjects
As part of a cross-sectional cohort study, 345 HIV-
infected Caucasian adults, 239 men and 106 women,
who were non-institutionalized, were evaluated in the
Endocrinology Outpatient Department of São João Hos-
pital, consecutively referred from the Infectious Diseases
Clinic. Patients were included on the first visit, and all
were on cART. The study protocol was approved by the
Hospital Ethics Committee for Health and all patients
provided informed consent.Clinical assessment
For each patient the following information was collected
using a standardized protocol: demographic data (age,
gender), duration of HIV infection, HIV infection risk
factors, duration of cART and characterization of the in-
fection. We used the “Centers for Disease Control and
Prevention” (CDC) criteria for classifying the degree of
infection [16]. Clinical history of diabetes, hypertension
and use of anti-diabetic, anti-hypertensive and lipid-
lowering drugs, as well as duration of cART, were also
evaluated. Weight, height, circumferences of neck, waist,
hip, thigh and arm were measured as previously pub-
lished [17-20]. Blood pressure (BP) was measured after 5
minutes seated, with the elbow flexed at the heart, using
a standard aneroid sphygmomanometer with the cuff on
the upper right arm. Two blood pressure readings were
taken and the mean of the two readings was calculated.
Body mass index (BMI) was calculated as weight divided
by height squared (kg/m2). Clinical lipodystrophy was
defined as a peripheral lipoatrophy with or without cen-
tral fat accumulation assessed by both patient and prac-
titioner, as we have previously described [17-20].
Presence of central fat accumulation or abdominal
prominence was defined by the measurement of waist
circumference using the International Diabetes Feder-
ation (IDF) criteria for metabolic syndrome [21].
Patients were classified into 4 different groups accord-
ing the presence or absence of either clinical lipoatrophy
or abdominal prominence: no lipodystrophy - patients
without clinical lipoatrophy and without abdominal
prominence; isolated central fat accumulation - patients
without clinical lipoatrophy and with abdominal promin-
ence; isolated lipoatrophy - patients with clinical lipoa-
trophy and without abdominal prominence; mixed forms
of lipodystrophy - patients with clinical lipoatrophy and
with abdominal prominence. The clinical assessment was
performed by the same practitioner (PF).
Evaluation of body composition
Body composition was also assessed with whole-body
dual–energy X-ray absorptiometry (DXA – Lunar Expert
XL). DXA measurement was performed while the pa-
tient was in a supine position, with standard positioning
of the arms and feet. Markers used in this study for
trunk and lower limbs that defined regions of interest
were those indicated by the manufacturer. Regional fat
mass values were grouped and analysed for the following
anatomical regions: arms, legs, trunk and total body.
The fat mass ratio (FMR) is the ratio of the percentage
of the trunk fat mass to the percentage of the lower limb
fat mass (FMR=% of the trunk fat mass/ % of the lower
limb fat mass) [22]. We define lipodystrophy by FMR
using the cut-off value of 1.961 threshold for men and
1.329 for women [17].The quantification of total,
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slice computed tomography (CT) scanner (Siemens Sen-
sation 64 Cardiac) with the same technique as previously
described [23,24]. All values were expressed in cm2
rounded to the nearest centesimal.
Laboratory analysis
A venous blood sample was drawn after a 12-hour over-
night fast. All the samples were analysed at the central
laboratory of our hospital. Patients without a previous
diagnosis of diabetes were submitted to a glucose toler-
ance test (OGTT). The test was performed as described
by the World Health Organization using a glucose load
containing the equivalent of 75 g anhydrous glucose dis-
solved in water.
Hepatitis C was diagnosed by HCV-Ab serostatus. The
CD4 cell count was determined by flow cytometry and
plasma HIV-1 RNA loads were measured by a quantita-
tive reverse transcriptase polymerase chain reaction
(Roche Diagnostic Systems, Inc., Branchburg, NJ, USA),
which has a lower limit of detection of 50 copies/mL.
Definition of the alterations of glucose metabolism
Diabetes was defined if two consecutive measurements
of fasting plasma glucose were ≥126 mg/dL and if 2 h
plasma glucose was ≥200 mg/dL during the oral glucose
tolerance test (OGTT).
Alterations of glucose metabolism were defined by
American Diabetes Association (ADA) 2009 criteria
[25]. We classified patients into 4 different categories of
glycaemic profile (normoglycaemia – NG, impaired fast-
ing glucose – IFG, impaired glucose tolerance – IGT
and diabetes mellitus type 2 – DM), according to plasma
glucose levels at 0’ and 120’ measured during OGTT.
Measurements of insulin resistance
IR was defined by the homeostasis model assessment of
insulin resistance (HOMA) and insulin sensitivity by the
quantitative insulin sensitivity check index (QUICKI)
and Matsuda index. These indexes were calculated using
the following formulas: HOMA IR index ¼
fasting insulin 0x fasting glucose0ð Þ=22:5 [26].HOMA B
index ¼ 20x insulin 0 mU=mLð Þð Þ= glucose 0 mMol=Lð Þð
3:5Þ [26].QUICKI ¼ 1=ðlog fasting insulin in mU=l½  þ
log fasting plasma glucose inmg=dL½  [27].Matsuda Index
¼10 000=sqrt glyc 0x insulin 0x glycmean x insulinmeanð Þ½ 
[28].Glucose expressed inmmol=L and insulin inmUI=mL.
IRwas definedwhen the value of HOMA > 4 [29,30].
Statistical analysis
Statistical analysis was performed using SPSS version
17.0 software (SPSS Inc., Chicago, Illinois, USA). All
probabilities were two tailed and p values <0.05 were
regarded as significant.Data were described as mean and standard deviation
(SD) for quantitative variables and compared using the
Student-t test or the Mann–Whitney test as appropriate.
Furthermore, analysis of variance or the Kruskal-Wallis
test were used for the comparison between quantitative
variables. Categorical variables were described as counts
and proportions, and compared using the chi-square or
Fisher’s exact test.
Spearman correlation coefficients were calculated to
estimate the associations between HOMA-IR and body
fat mass evaluated either by CT or DXA.
After log transformation, linear regression models
were computed for estimating the association between
FMR and HOMA score, fasting and 2 hours glucose and
A1C levels. Models were adjusted for age, sex, current
antiretroviral therapy [protease inhibitor (PI), nucleoside
reverse transcriptase inhibitor (NRTI), non-nucleoside
reverse transcriptase inhibitor (NNRTI)], CD4 count
cells and plasma HIV-1 RNA load.
Results
Baseline characteristics
A total of 345 HIV-infected patients on cART were eval-
uated with a mean age of 45.0 ± 11.3 years. 69.3 % were
males. The demographic and clinical characteristics of
the patients included in this study, according to the
presence of lipodystrophy are shown in Table 1.
Patients with clinical lipodystrophy (CL) were older,
had higher duration of HIV infection and length of
cART. Regarding anthropometric measures, patients
with CL had lower BMI, waist, hip, thigh, and arm cir-
cumferences. Patients with CL had higher CD4+ cell
count and percentage of viral suppression. With regards
to the risk of HIV transmission in patients with CL,
heterosexuality was responsible for 52.9 %, followed by
drug addiction in 30.6 %, homo-bisexuality in 11.2 %.
In the remaining cases, haemophilia, transfusions and
unknown causes were responsible for 1.2 %, 1.2 % and
2.9 %, respectively. Similarly, in patients without CL,
heterosexuality was also the leading cause with 65.8 %,
followed by drug addiction, homo-bisexuality and un-
known causes in 24.6 %, 8.8 % and 0.9 %, respectively.
No significant difference was observed in lipodystrophic
patients according to HIV risk transmission. The preva-
lence of co-infection was similar in patients with and
without lipodystrophy [clinically- (Table 1) or FMR-
defined (data not shown)]. Nevertheless, patients with no
lipodystrophy and with isolated peripheral lipoatrophy
exhibited a higher proportion of hepatitis C co-infection
when compared to the other two groups (Table 2).
There was a significant difference in the different
stages of CDC criteria between patients with or without
lipodystrophy, with the majority of patients being in
groups A or C. No differences were observed in the type
Table 1 Sample characteristics according to the presence
of clinical lipodystrophy
Without CL With CL P
n (%) 139 206
Gender [n (%)]
Male 85 (61.2) 154 (74.8) 0.007
Female 54 (38.8) 52 (25.2)
Age [years, mean (sd)] 44.2 (12.1) 46.9 (10.7) 0.007
Duration of HIV infection
[years, median (IQR)]
6.0 (5.0) 9.0 (5.0) <0.001
cART [years, median (IQR)] 4.0 (5.0) 8.0 (5.0) <0.001
Weight [Kg, mean (sd)] 73.7 (14.1) 66.2 (12.4) <0.001
Height [m, mean (sd)] 1.65 (0.09) 1.66 (0.09) 0.368
BMI [(kg/m2), median (IQR)] 26.3 (5.9) 23.8 (5.1) <0.001
Waist circumference [cm, median (IQR)] 94.0 (17.0) 89.0 (14.5) <0.001
Hip circumference [cm, median (IQR)] 99.0 (11.0) 91.0 (9.0) <0.001
Thigh circumference [cm, mean (sd)] 50.0 (5.5) 46.1 (6.1) <0.001
Arm circumference [cm, mean (sd)] 28.1 (3.1) 26.6 (4.1) <0.001
Neck circumference [cm, mean (sd)] 37.2 (3.7) 37.1 (4.0) 0.940
CD4 cell count [cells/mm3,
median (IQR)]
446.5 (342.2) 544.0 (387.0) 0.008
HIV RNA (<50) [n (%)] 93 (81.6) 163 (91.1) 0.017
Smoking history [n (%)]
Never 61 (44.2) 70 (34.8) 0.219
Current 55 (39.9) 93 (46.3)
Former 22 (15.9) 38 (18.9)
HIV risk factor [n (%)]
Injecting drug user 28 (24.6) 52 (30.6) 0.247
Homosexual contact 10 (8.8) 19 (11.2)
Heterosexual contact 76 (65.8) 90 (52.9)
Others 1 (0.9) 9 (5.3)
Hepatitis C co-infection [n (%)] 31 (25.2) 58 (31.4) 0.300
CDC [n (%)]
A 62 (54.9) 94 (53.4) 0.037
B 4 (3.5) 0 (0)
C 47 (41.6) 82 (46.6)
ART [n (%)]
IP 67 (61.5) 98 (55.4) 0.310
NNRTI 47 (43.1) 83 (46.9) 0.534
NRTI 104 (95.4) 175 (98.9) 0.110
Hypoglycemic therapy [n (%)]
Oral anti-diabetic drugs 10.1 % (14) 14.6 % (30) 0.132
Insulin 4.3 % (6) 7.3 % (15) 0.261
Body fat mass by quantitative CT
Total fat [cm2, median (IQR)] 340.5 (196.6) 213.6 (175.2)<0.001
Central fat [cm2, median (IQR)] 110.8 (111.4) 114.8 (120.5) 0.800
Peripheral fat [cm2, median (IQR)] 186.2 (172.0) 78.7 (104.9)<0.001
Table 1 Sample characteristics according to the presence
of clinical lipodystrophy (Continued)
Central/peripheral fat ratio [cm2,
median (IQR)]
0.51 (0.55) 1.34 (2.15) <0.001
FMR by DXA [median (IQR)] 1.06 (0.57) 1.79 (1.37) <0.001
(CL- clinical lipodystrophy; CDC - Centers for Disease Control and Prevention
criteria for staging of HIV infection -; cART- combined antiretroviral therapy;
BMI- body mass index; FMR – fat mass ratio; DXA –dual-energy X-ray
absorptiometry ; CT – computed tomography; PI – protease inhibitor; NNRTI
–non-nucleoside reverse transcriptase inhibitor; NRTI – nucleoside reverse
transcriptase inhibitor).
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hypoglycaemic therapy (oral anti-diabetic drug and insu-
lin). FMR evaluated by DXA was higher in patients with
CL. When body fat mass was evaluated using quantita-
tive CT, patients with CL had lower total and peripheral
fat, but higher central/peripheral fat ratio than patients
without CL.
No differences in smoking status between patients
with or without lipodystrophy [clinically- (Table 1) or
FMR-defined (data not shown)] were found. Patients
with no lipodystrophy and with isolated peripheral lipoa-
trophy were more frequently current smokers when
compared to the other two groups (Table 2).
Insulin resistance
No significant differences in the means of HOMA-IR,
QUICKI, MATSUDA, insulin and A1c were observed
between patients with and without CL. In fact, regarding
the alterations of glucose metabolism, only for fasting
glucose was there a trend for significantly higher values
in CL. On the other hand, when lipodystrophy was
defined by FMR, all indicators of insulin resistance and
glucose metabolism were significantly associated with
lipodystrophy with the obvious exception of QUICKI
and MATSUDA indices (Table 3).
Higher prevalence of insulin resistance, defined as
HOMA-IR ≥ 4, was observed in patients with lipody-
strophy defined by FMR (p = 0.019) but not when
lipodystrophy was clinically defined. Similar results
were observed when we compared the prevalence of
HOMA score thirds according to the definition of
lipodystrophy. Again, only when lipodystrophy was
defined by the FMR were the differences between
HOMA score thirds statistically significant (p = 0.002)
(Table 4).
Glucose homeostasis abnormalities
When we classified patients into the 4 ADA categories
of glycaemic profile, no significant differences were
found between these categories in patients with or
without CL. However, patients with lipodystrophy
defined by FMR had a higher prevalence of IFG, IGT
and DM when compared to patients without
Table 2 Smoking history and hepatitis C co-infection according to the four groups of body fat distribution
No
lipodystrophy
Isolated central
fat accumulation
Isolated peripheral
lipoatrophy
Mixed forms of
lipodystrophy
P
Smoking history [n (%)]
Never 14 (28.0) 46 (52.9) 24 (22.4) 45 (48.4) <0.001
Current 30 (60.0) 25 (28.7) 67 (62.6) 26 (28.0)
Former 6 (12.0) 16 (18.4) 16 (15.0) 22 (23.7)
Hepatitis C co-infection [n (%)] 19 (45.2) 12 (14.8) 46 (47.9) 11 (12.5) <0.001
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into 4 groups of fat distribution (presence or not of
clinical lipoatrophy and abdominal prominence), no
differences were observed in glycaemic profile. How-
ever, when we divided patients according to the 4 cat-
egories of fat distribution (presence or not of
lipodystrophy defined by FMR and abdominal promin-
ence), patients with abdominal prominence independ-
ent of the presence of lipodystrophy had higher IGT.
Moreover, the highest prevalence of DM was observed
in patients with lipodystrophy and abdominal promin-
ence (Table 6).Association between HOMA-IR and body fat mass
evaluated by CT and DXA
After log transformation, significant associations were
found between total fat, central fat and central/periph-
eral fat ratio evaluated by CT at abdominal level and
HOMA-IR. These associations remained significant after
adjustments for age, gender, PI, NRTI, NNRTI, CD4 cell
count and HIV-1 RNA viral load. On the other hand, no
significant association was found between IR and periph-
eral fat. Similar results were observed when fat distribu-
tion was evaluated by DXA. Significant associations were
found between total, trunk and arm fat mass evaluated
by DXA and HOMA-IR. Also, these associations
remained significant after adjustments for age, gender,
PI, NRTI, NNRTI, CD4 cell count and HIV-1 RNA viral
load (Table 7).Table 3 Insulin resistance indices according to lipodystrophy
Lipodystrophy defined clinically
Total Without CL W
HOMA-IR [median (IQR)] 1.9 (2.8) 1.7 (2.4)
HOMA-B [median (IQR)] 92.3 (106.4) 92.3 (91.1) 9
QUICKI [median (IQR)] 0.34 (0.06) 0.35 (0.06) 0
MATSUDA [median (IQR)] 4.8 (5.1) 5.0 (4.2)
Glucose [mg/dL, median (IQR)] 93.5 (26.0) 90.0 (23.0) 9
Insulin [μU/mL, median (IQR)] 8.1 (9.6) 7.9 (8.2)
A1c [% median (IQR)] 5.3 (0.7) 5.2 (0.6)
(CL- clinical lipodystrophy; L- lipodystrophy).Association between FMR and glycaemic parameters and
insulin resistance
After log transformation, a significant positive linear as-
sociation was observed between FMR and insulin resist-
ance evaluated by HOMA. This association was
independent of age, gender, IP, NRTI, NNRTI, CD4 cell
count and HIV-1 RNA viral load. No significant associ-
ation was observed with the glycaemic parameters
(Table 8). We performed linear regression models of the
association between FMR and the variables described
above, after excluding patients that were on anti-diabetic
or insulin therapy, and similar results were obtained
(data not shown).
Discussion
We compared the prevalence of glucose homeostasis dis-
turbances and IR in HIV-infected patients on cART,
according to the presence of lipodystrophy (clinically and
FMR defined) and according to the four different pat-
terns of body fat distribution previously described. In our
study, all the participants were evaluated by the same ob-
server (PF) to increase the accuracy in the clinical defin-
ition of lipodystrophy [22]. We also used an objective
method to evaluate lipodystrophy to overcome the differ-
ent and heterogeneous methodologies for the diagnosis
of lipodystrophy of previous studies [31]. Since lipody-
strophy in HIV-1 infected patients is considered to be an
adverse effect of cART, not limited to a specific drug or a
class of drugs [32], we chose to study only patients on
cART, since our main goal was to compare thedefined clinically and by FMR
defined by FMR
ith CL P Without L With L P
2.1 (3.0) 0.229 1.6 (2.6) 2.8 (2.8) <0.001
1.8 (117.5) 0.855 92.3 (96.1) 85.4 (120.8) 0.633
.34 (0.06) 0.229 0.36 (0.07) 0.33 (0.05) <0.001
4.7 (5.4) 0.735 5.9 (5.3) 4.1 (4.4) 0.002
7.0 (35.5) 0.046 90.0 (23.0) 97.0 (35.5) 0.002
9.0 (10.2) 0.365 7.5 (8.1) 10.1 (9.9) 0.003
5.3 (0.9) 0.091 5.2 (0.6) 5.5 (0.9) 0.002
Table 4 Insulin resistance according to lipodystrophy defined clinically and by FMR
Lipodystrophy defined clinically Lipodystrophy defined by FMR
Without CL With CL P Without L With L P
HOMA –IR
< 4 [n (%)] 93 (80.9) 121 (71.6) 0.075 94 (80.3) 58 (65.9) 0.019
≥ 4 [n (%)] 22 (19.1) 48 (28.4) 23 (19.7) 30 (34.1)
Thirds of HOMA-IR
1 40 (34.8) 55 (32.5) 0.222 51 (43.6) 18 (20.5) 0.002
2 43 (37.4) 51 (30.2) 34 (29.1) 33 (37.5)
3 32 (27.8) 63 (37.3) 32 (27.4) 37 (42.0)
(CL- clinical lipodystrophy; L- lipodystrophy).
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according to the presence of lipodystrophy. No differ-
ences were observed between the class of drugs used
in patients with or without CL, defined either clinically
or by FMR (data not shown). Also, similar results were
observed when the comparison was performed in
patients with and without lipodystrophy defined by
FMR (data not shown). Despite the euglycaemic-
hyperinsulinaemic clamp being the gold standard tech-
nique for estimation of IR [33], we used simple
methods that have shown a good correlation with
the gold standard method (HOMA-IR, QUICKI and
MATSUDA) [28,34]. There are studies comparing the
prevalence of DM in HIV patients and the general
population, and comparing ART-naïve HIV-infected
patients with the general population, but fewer com-
pared this prevalence between patients with or without
lipodystrophy.
When patients were classified as being lipodystrophic
or not, according to FMR, we observed that patients
with lipodystrophy had higher IR (higher HOMA and
lower QUICKI and Matsuda values). Matsuda index
seems to have a greater ability to predict diabetes than
its HOMA equivalents [34]. They also had higher fasting
plasma glucose, insulin and A1C levels, and higher % of
IFG, IGT and DM. When we categorised patients into 4
categories of body fat distribution using FMR-defined
lipodystrophy and waist circumference, those patients
with lipodystrophy and abdominal prominence hadTable 5 Prevalence of glucose homeostasis abnormalities acc
Lipodystrophy defined clinically
Total (n = 228) Without CL (n = 89) With CL (n =
NG [n (%)] 117 (49.1) 44 (49.4) 63 (48.8)
IFG [n (%)] 18 (8.3) 10 (11.2) 8 (6.2)
IGT [n (%)] 49 (22.5) 21 (23.6) 28 (21.7)
DM [n (%)] 44 (20.2) 14 (15.7) 30 (23.3)
(NG- normal glucose; IFG – impaired fasting glucose: IGT – impaired glucose toleran
L-lipodystrophy).higher prevalence of DM and IGT. Patients without
FMR-defined lipodystrophy but with abdominal promin-
ence only had a high prevalence of IGT. It seems that
the loss of peripheral adipose tissue is less important
than the presence of abdominal prominence in the oc-
currence of IR. However, the role of peripheral adipose
tissue cannot be completely precluded, since patients
with abdominal prominence only and without lipody-
strophy, defined by FMR, had less marked glucose dis-
turbances i.e. they only had increased prevalence of IGT.
The discrepancy observed between the results obtained
using the 2 different lipodystrophy definitions (Tables 3,
5 and 6) could result from the higher accuracy of the ob-
jective method in detecting slight losses of peripheral
adipose tissue that were not detected by clinical inspec-
tion, as has been previously proposed by Bonnet [22].
Significant associations between IR and total fat, cen-
tral fat and central/peripheral fat ratio and no associ-
ation with peripheral fat at abdominal level evaluated by
CT were observed, emphasizing the contribution of the
central fat mass to IR. We found an association between
IR and total and trunk fat evaluated by DXA. As in our
results, De Wit et al. showed that clinical lipodystrophy
was significantly associated with new-onset diabetes and
the abnormal body fat distribution in HIV-positive indi-
viduals is strongly associated with IR and/or glucose in-
tolerance, with excess trunk or visceral fat being, as in
the general population, an important risk factor for IR
among those with HIV infection. In addition, De Witording to lipodystrophy defined clinically and by FMR
Lipodystrophy defined by FMR
129) P Without L (n = 100) With L (n = 70) P
0.364 62 (62.0) 29 (41.4) 0.021
5 (5.0) 11 (15.7)
19 (19.0) 15 (21.4)
14 (14.0) 15 (21.4)
ce; DM – diabetes mellitus; CL – clinical lipodystrophy; L – lipodystrophy;
Table 6 Prevalence of glucose homeostasis abnormalities according to body composition categorised into 4 groups of
fat distribution
Categories of fat distribution by clinical lipoatrophy and WC Categories of fat distribution by FMR and WC
CLA- AP- CLA-AP+ CLA+AP- CLA+AP+ P L- AP- L-AP+ L+AP- L +AP+ P
NG [n (%)] 17 (56.7) 27 (45.8) 41 (58.6) 22 (37.3) 0.064 39 (61.9) 32 (50.8) 19 (51.4) 17 (30.9) 0.002
IFG [n (%)] 1 (3.3) 9 (15.3) 4 (5.7) 4 (6.8) 0 (0.0) 7 (11.1) 5 (13.5) 6 (10.9)
IGT [n (%)] 5 (16.7) 16 (27.1) 10 (14.3) 18 (30.5) 9 (14.3) 17 (27.0) 6 (16.2) 17 (30.9)
DM [n (%)] 7 (23.3) 7 (11.9) 15 (21.4) 15 (25.4) 15 (23.8) 7 (11.1) 7 (18.9) 15 (27.3)
(NG- normal glucose; IFG – impaired fasting glucose: IGT – impaired glucose tolerance; DM – diabetes mellitus; CLA – Clinical lipoatrophy; AP – abdominal
prominence defined by waist circumference >80 cm in women and >94 cm in men – IDF 2005; L- lipodystrophy FMR defined; CLA-AP-: no lipodystrophy;
CLA-AP+: isolated central fat accumulation; CLA +AP-: isolated lipoatrophy; CLA +AP+: mixed forms of lipodystrophy).
Freitas et al. BMC Infectious Diseases 2012, 12:180 Page 7 of 10
http://www.biomedcentral.com/1471-2334/12/180observed that IR is itself independently associated with
fat loss in HIV-positive individuals [5].
In our sample, no association was observed between
peripheral fat mass and IR (Table 7). This result is con-
trary to that of the De Wit study, where patients had a
marked peripheral adipose tissue loss that was clinically
evident. Also, our patients may have had less evident
loss of fat mass, which was detected by FMR. In fact,
according to De Wit’s conclusions, information on lipo-
dystrophy was rarely collected since the study was car-
ried out in 11 centres, which may suggest that only
marked lipodystrophies were reported.
The dual contribution of peripheral fat loss and
increased abdominal fat has also been described by other
authors [35-38]. Furthermore, hyperinsulinaemia seems
to be more severe among the patients with a combined
fat redistribution syndrome.
In our HIV-infected sample, we had a high prevalence
of diabetes (20.2 %), of IGT (22.5 %) and IFG (8.3 %).
This high prevalence could not be extrapolated for the
total HIV population since we could have a referral bias,
but we would like to emphasize that our aim was toTable 7 Association between HOMA-IR and body fat mass
evaluated by CT and DXA
Crude model Model 1* Model 2**
β P β P β p
Body Fat Mass by Quantitative CT
Total Fat 0.384 0.001 0.419 0.001 0.415 0.001
Central Fat 0.516 <0.001 0.486 <0.001 0.490 <0.001
Peripheral Fat 0.050 0.530 0.127 0.168 0.114 0.222
Central/peripheral fat ratio 0.258 0.001 0.239 0.015 0.262 0.008
Body fat mass by DXA
Total 0.247 0.024 0.374 0.002 0.420 0.001
Trunk 0.403 <0.001 0.467 <0.001 0.502 <0.001
Leg −0.043 0.625 0.049 0.653 0.087 0.438
Arm 0.162 0.058 0.352 0.001 0.366 0.001
*-Mode1: adjusted for age and gender.
**-Model 2: adjusted for age, gender, IP, NRTI, CD4 cell count and HIV-1 RNA
viral load.
(DXA –dual-energy X-ray absorptiometry; CT – computed tomography).evaluate the prevalence of glucose homeostasis distur-
bances and IR according to the presence of lipodystro-
phy. In HIV-infected patients, some studies showed a
low prevalence of diabetes, around 3.0 %, but without
performing OGTT, which could have resulted in some
under-identification of glucose disturbances [39]. Others
suggested that the prevalence and incidence of diabetes
was higher (10-14 %) [7,8,40-42] but still lower than that
which we observed. Concerning HIV-associated lipody-
strophy, Carr found a baseline diabetes prevalence of
2 % [43] and an over threefold increase after 14 months
of follow-up [44], which suggests that lipodystrophy
strongly promotes the progression to hyperglycaemia.
The overall prevalence of all glucose disturbances (DM,
IFG and IGT) was 25 % [43]. In the Lipodystrophy Case
Definition Study, diabetes prevalence was 7 % in those
with lipodystrophy and 3 % in those without [45].
It is extremely difficult to determine which drug is re-
sponsible for the risk of diabetes because they are always
used in combination and therapeutic changes in individ-
ual participants often occur during the course of the dis-
ease. The results are generally consistent, indicating a
higher risk of diabetes with use of NRTI and NNRTI
[46,47]. Also, others have shown that regimens contain-
ing PI are associated with new-onset diabetes and IR
[48,49]. cART has direct effects on glucose metabolism,
or exerts its effect on glucose metabolism indirectly by
affecting changes in body composition. PIs directly and/
or indirectly alter body composition, lipid profile, adipo-
kine levels, and mediators of inflammation. The newerTable 8 Association between FMR and glycaemic
parameters and insulin resistance
Crude model Model 1* Model 2**
β P β P β p
HOMA 0.589 <0.001 0.595 0.001 0.266 0.002
Glucose 0´ 0.124 0.002 0.041 0.367 0.098 0.222
Glucose 2 h 0.079 0.142 0.086 0.139 0.149 0.104
A1C 0.053 0.015 0.007 0.765 0.083 0.314
*-Mode1: adjusted for age and gender.
**-Model 2: adjusted for age, gender, IP, NRTI, CD4 cell count and HIV-1 RNA
viral load.
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than older regimens.
In our study, FMR as a continuum was significantly
associated with insulin resistance evaluated by HOMA,
even after adjustment for gender, age, IP, NRTI, NNRTI,
CD4 cell count and HIV RNA viral load. No association
between clinical and FMR-defined lipodystrophy and
glycaemic parameters was observed.
The association between fat redistribution, glucose dis-
turbances, IR and cART, might be explained through sev-
eral mechanisms: lipoatrophy per se; lipotoxicity (cART
or visceral fat-induced or both, demonstrated by
increased lipolysis and circulating free fatty acids) [2]; in-
flammation (resulting from the infection and demon-
strated by increased TNF-alpha production, increased
serum concentrations of the soluble type 2 receptor of
TNF-alpha [39] and other interleukins), and hormonal
factors (leptin, resistin or adiponectin).
We should keep in mind that IR and diabetes are
associated with age, so increased life expectancy with
the use of cART is likely to increase the prevalence of
diabetes [7].
The net risk of diabetes mellitus is determined by a com-
plex interplay of individual factors, combining the trad-
itional risk factors and newer risk factors associated with
HIV-infected patients on cART. The clinical implications
and message should be the need to aggressively screen for,
prevent, and treat diabetes mellitus among HIV-infected
patients because the presence of diabetes increases the risk
of a future CHD event by almost 2.5 times [7].Our study has some limitations
Although all patients referred from Infectious Diseases
to our department were included, bias in the referral
cannot be excluded, since some patients could have been
referred because they had some degree of glucose in-
tolerance or dyslipidaemia. It was not our aim to deter-
mine the prevalence of glucose homeostasis disturbances
in the HIV population, because these patients are not
representative of the general HIV population in our
country. Our aim was to compare the prevalence of glu-
cose homeostasis disturbances and IR in HIV-infected
patients according the presence of lipodystrophy and to
different patterns of fat distribution.
Also, information regarding other important risk factors
for DM (e.g. family history, physical inactivity) was not col-
lected and could not be analysed. Some drugs used for
managing complications of HIV infection may be asso-
ciated with worsening IR or DM; we believe that if there
was any effect it was very small, since none of our patients
were on niacin, megestrol acetate or steroids, and only
some of them were on thiazides for the management of
hypertension.Some aspects of this study should be highlighted
The study was performed in a unit that is highly experi-
enced in the assessment of metabolic and body fat ab-
normalities in HIV-infected patients; the clinical
assessment of lipodystrophy was carried out by the same
investigator (PF); and an objective definition of lipody-
strophy (Fat Mass Ratio by DXA), visceral and subcuta-
neous fat mass by CT was used.
Conclusions
Insulin resistance and glucose homeostasis abnormalities
significantly increased with increasing FMR. Abdominal
prominence, measured by abdominal circumference,
waist/hip ratio, visceral and trunk fat defined by CT, was
also associated with glucose homeostasis disturbances.
Although no association between glucose disturbances
and IR was observed in clinically defined lipodystrophy,
when this condition was defined by FMR, a significant
positive association was observed.
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